<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.28996/1680-4422-2017-4-512-521</article-id><article-id custom-type="elpub" pub-id-type="custom">nid-413</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ШКОЛА НЕФРОЛОГА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EDUCATIONAL MATERIALS</subject></subj-group></article-categories><title-group><article-title>Частота и длительность гемодиализа у пациентов с остаточной функцией почек</article-title><trans-title-group xml:lang="en"><trans-title>Frequency and duration of hemodialysis in patients with residual renal function</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Асанбек К.</surname><given-names>А. .</given-names></name><name name-style="western" xml:lang="en"><surname>Asanbek K.</surname><given-names>A. .</given-names></name></name-alternatives><email xlink:type="simple">iperyipery@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ошский Государственный университет; Центр Гемодиализа ЮРФА</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Osh State University Medical Clinic; Hemodialysis Center YURFA</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>16</day><month>08</month><year>2024</year></pub-date><volume>19</volume><issue>4</issue><fpage>512</fpage><lpage>521</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Асанбек К. А..., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Асанбек К. А...</copyright-holder><copyright-holder xml:lang="en">Asanbek K. A...</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/413">https://journal.nephro.ru/jour/article/view/413</self-uri><abstract><p>Остаточная функция почек у пациентов на заместительной почечной терапии гемодиализом имеет важное значение в прогнозе выживаемости. Многочисленные исследования подтверждают связь между величиной остаточной функцией почек и улучшением качества жизни на заместительной почечной терапии как гемодиализом, так и перитонеальным диализом. Однако возникает вопрос - возможно ли снижение кратности и/или длительности процедур при относительно значимой остаточной функции почек? В большинстве руководств по гемодиализу рекомендуется корректировать диализную дозу для пациентов со скоростью клубочковой фильтрации более 2 мл/мин/1,73 м2, но точные параметры эффективного диализного времени не указываются. Наиболее изучена в этом плане модальность двухразового гемодиализа. Если в экономически развитых странах двухразовый гемодиализ применяется редко и, в основном, связан с желанием пациентов ограничить время, занятое на процедуры и транспортировку, то в ряде развивающихся стран двухразовый гемодиализ связан с экономическими ограничениями. Наблюдательные исследования, посвященные сравнению эффективности двухразового и стандартного трехразового гемодиализа у пациентов со значимой остаточной функцией почек, выявили лучшее влияние двухразового гемодиализа на такие исходы как смертность, количество госпитализаций, качество жизни в первый год лечения. Цель данного обзора - представить данные по обоснованности двухразового гемодиализа и влияние его на смертность, количество госпитализаций и качество жизни больных с остаточной функцией почек на гемодиализе, а также рассмотреть условия исследований, которые проводились по данному вопросу, и применяемость их результатов в повседневной практике.</p></abstract><trans-abstract xml:lang="en"><p>Residual renal function (RRF) in patients on renal replacement therapy (RRT) with hemodialysis plays an important positive role in the survival prognosis. Many studies confirm the relationship between the RRF and the improvement of quality of life on RRT, both with hemodialysis and peritoneal dialysis. However, it poses the following question: is it possible to reduce the frequency and/or duration of procedures in patients with a significant RRF? In most guidelines on hemodialysis, it is recommended to adjust the dialysis dose for patients with a glomerular filtration rate of more than 2 ml/min/1.73 m2. However, parameters of effective dialysis duration are not defined. The twice-a-week modality of hemodialysis is the most studied in this respect. The twice-a-week hemodialysis is rarely used in Europe and the USA, where it is mainly associated with patient's will to limit the time spent for the procedures and transportation. In a number of developing countries, it is associated with economic constraints. Studies comparing the efficacy of twice-weekly and standard three times a week hemodialysis in patients depending on the RRF, revealed a better effect of twice-a-week hemodialysis on outcomes such as mortality, number of hospitalizations, and health-related quality of life in the first year of treatment. The aim of this review is to identify the validity of twice-a-week hemodialysis and its impact on mortality, the number of hospitalizations and the health-related quality of life in patients with RRF. We considered the studies in this field and the applicability of their results in daily practice.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>гемодиализ</kwd><kwd>частота сеансов</kwd><kwd>остаточная функция почек</kwd><kwd>качество жизни пациентов</kwd><kwd>смертность</kwd><kwd>количество госпитализаций</kwd><kwd>диализная доза</kwd><kwd>hemodialysis</kwd><kwd>residual renal function</kwd><kwd>health-related quality of life of patients</kwd><kwd>mortality</kwd><kwd>the number of hospitalizations</kwd><kwd>dialysis dose</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Бикбов Б.Т., Томилина Н.А. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 1998-2013 гг. Отчет по данным Российского регистра заместительной почечной терапии. Часть первая. Нефрология и Диализ. 2015. №3: 5-111. Bikbov B.T., Tomilina N.A. Renal replacement therapy for ESRD in Russian Federation, 1998-2013 Report of the Russian Renal Replacement Therapy Registry. Part 1. Nephrology and dialysis. 2015. №3: 5-111.</mixed-citation><mixed-citation xml:lang="en">Бикбов Б.Т., Томилина Н.А. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 1998-2013 гг. Отчет по данным Российского регистра заместительной почечной терапии. Часть первая. Нефрология и Диализ. 2015. №3: 5-111. Bikbov B.T., Tomilina N.A. Renal replacement therapy for ESRD in Russian Federation, 1998-2013 Report of the Russian Renal Replacement Therapy Registry. Part 1. Nephrology and dialysis. 2015. №3: 5-111.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Земченков А.Ю. Вишневский К.А. Сабодаш А.Б. Сроки начала и другие факторы на старте диализа, влияющие на выживаемость: Санкт-Петербургский регистр пациентов на заместительной почечной терапии. Нефрология и диализ. 2017. Т. 19 № 2: 255-270. A.Yu. Zemchenkov, K.A. Vishnevskii, A.B. Sabodash. The timing and other dialysis start features associated with survival: St-Petersburg renal replacement therapy register. Nephrology and dialysis. 2017. Т. 19 № 2: 255-270.</mixed-citation><mixed-citation xml:lang="en">Земченков А.Ю. Вишневский К.А. Сабодаш А.Б. Сроки начала и другие факторы на старте диализа, влияющие на выживаемость: Санкт-Петербургский регистр пациентов на заместительной почечной терапии. Нефрология и диализ. 2017. Т. 19 № 2: 255-270. A.Yu. Zemchenkov, K.A. Vishnevskii, A.B. Sabodash. The timing and other dialysis start features associated with survival: St-Petersburg renal replacement therapy register. Nephrology and dialysis. 2017. Т. 19 № 2: 255-270.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Осипова М.В., Дмитриев А.А., Кириченко А.А. Особенности и возможности коррекции артериальной гипертензии препаратом эналаприл у больных, находящихся на программном гемодиализе, в зависимости от остаточной функции почек. Вестник трансплантологии и искусственных органов. 2007. Т. 9. № 3: 25-30. Osipova M.V., Dmitriev A.A., Kirichenko A.A. Osobennosti i vozmozhnosti korrekcii arterial'noj gipertenzii preparatom ehnalapril u bol'nyh, nahodyashchihsya na programmnom gemodialize, v zavisimosti ot ostatochnoj funkcii pochek. Vestnik transplantologii i iskusstvennyh organov. 2007. T. 9. № 3: 25-30.</mixed-citation><mixed-citation xml:lang="en">Осипова М.В., Дмитриев А.А., Кириченко А.А. Особенности и возможности коррекции артериальной гипертензии препаратом эналаприл у больных, находящихся на программном гемодиализе, в зависимости от остаточной функции почек. Вестник трансплантологии и искусственных органов. 2007. Т. 9. № 3: 25-30. Osipova M.V., Dmitriev A.A., Kirichenko A.A. Osobennosti i vozmozhnosti korrekcii arterial'noj gipertenzii preparatom ehnalapril u bol'nyh, nahodyashchihsya na programmnom gemodialize, v zavisimosti ot ostatochnoj funkcii pochek. Vestnik transplantologii i iskusstvennyh organov. 2007. T. 9. № 3: 25-30.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Arora P, Rajagopalan S, Patel N, et al. The MDRD equation underestimates the prevalence of CKD among blacks and overestimates the prevalence of CKD among whites compared to the CKD-EPI equation: a retrospective cohort study. BMC Nephrology. 2012. 13: 4.</mixed-citation><mixed-citation xml:lang="en">Arora P, Rajagopalan S, Patel N, et al. The MDRD equation underestimates the prevalence of CKD among blacks and overestimates the prevalence of CKD among whites compared to the CKD-EPI equation: a retrospective cohort study. BMC Nephrology. 2012. 13: 4.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">B. A. Cooper, P. Branley, L. Bulfone. A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis. N Engl J Med. 2010. 363: 609-619</mixed-citation><mixed-citation xml:lang="en">B. A. Cooper, P. Branley, L. Bulfone. A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis. N Engl J Med. 2010. 363: 609-619</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bello AK, Levin A, Tonelli M, et al. Assessment of Global Kidney Health Care Status. JAMA. 2017. 317(18): 1864-1881.</mixed-citation><mixed-citation xml:lang="en">Bello AK, Levin A, Tonelli M, et al. Assessment of Global Kidney Health Care Status. JAMA. 2017. 317(18): 1864-1881.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Bieber B, Qian J, Anand S, et al. Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and Quality of Life in the China Dialysis Outcomes and Practice Patterns study. Nephrology Dialysis Transplantation. 2014. 29(9): 1770-1777.</mixed-citation><mixed-citation xml:lang="en">Bieber B, Qian J, Anand S, et al. Two-times weekly hemodialysis in China: frequency, associated patient and treatment characteristics and Quality of Life in the China Dialysis Outcomes and Practice Patterns study. Nephrology Dialysis Transplantation. 2014. 29(9): 1770-1777.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Caskey F, Castledine C, Dawnay A,et al. UK Renal Registry 18th Annual Report of the Renal Association. AJ UK Renal Registry, Bristol, UK NEPHRON. 2016. 132 (suppl1).</mixed-citation><mixed-citation xml:lang="en">Caskey F, Castledine C, Dawnay A,et al. UK Renal Registry 18th Annual Report of the Renal Association. AJ UK Renal Registry, Bristol, UK NEPHRON. 2016. 132 (suppl1).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cockcroft D.W. and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976. 16: 31-41</mixed-citation><mixed-citation xml:lang="en">Cockcroft D.W. and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976. 16: 31-41</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000 Jul. 36(1): 29-34.</mixed-citation><mixed-citation xml:lang="en">Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000 Jul. 36(1): 29-34.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dimitris Xydakis, Apostolos Papadogiannakis, Maria Sfakianaki, et al. Residual Renal Function in Hemodialysis Patients: The Role of Angiotensin-Converting Enzyme Inhibitor in Its Preservation, ISRN Nephrology. 2013. Article ID 184527: 5.</mixed-citation><mixed-citation xml:lang="en">Dimitris Xydakis, Apostolos Papadogiannakis, Maria Sfakianaki, et al. Residual Renal Function in Hemodialysis Patients: The Role of Angiotensin-Converting Enzyme Inhibitor in Its Preservation, ISRN Nephrology. 2013. Article ID 184527: 5.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Drechsler C, de Mutsert R, Grootendorst DC, et al. NECOSAD Study Group. Association of body mass index with decline in residual kidney function after initiation of dialysis. Am J Kidney Dis. 2009. 53(6): 1014-23.</mixed-citation><mixed-citation xml:lang="en">Drechsler C, de Mutsert R, Grootendorst DC, et al. NECOSAD Study Group. Association of body mass index with decline in residual kidney function after initiation of dialysis. Am J Kidney Dis. 2009. 53(6): 1014-23.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Dworkin LD, Berstein JA, Parker M, et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int. 1993. 43: 808-814.</mixed-citation><mixed-citation xml:lang="en">Dworkin LD, Berstein JA, Parker M, et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int. 1993. 43: 808-814.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Effersøe P. Relationship between Endogenous 24-hour Creatinine Clearance and Serum Creatinine Concentration in Patients with Chronic Renal Disease. Acta Medica Scandinavica. 1957. 156: 429-434.</mixed-citation><mixed-citation xml:lang="en">Effersøe P. Relationship between Endogenous 24-hour Creatinine Clearance and Serum Creatinine Concentration in Patients with Chronic Renal Disease. Acta Medica Scandinavica. 1957. 156: 429-434.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández Lucas M, Teruel JL. Hemodiálisis incremental como forma de inicio del tratamiento sustitutivo renal. Nefrología. 2017.</mixed-citation><mixed-citation xml:lang="en">Fernández Lucas M, Teruel JL. Hemodiálisis incremental como forma de inicio del tratamiento sustitutivo renal. Nefrología. 2017.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Fontseré N, Bonal J, Navarro M, et al. A comparison of prediction equations for estimating glomerular filtration rate in adult patients with chronic kidney disease stages 4-5. Effect of nutritional status and age. Nephron Clin Pract. 2006.104(4):160-8.</mixed-citation><mixed-citation xml:lang="en">Fontseré N, Bonal J, Navarro M, et al. A comparison of prediction equations for estimating glomerular filtration rate in adult patients with chronic kidney disease stages 4-5. Effect of nutritional status and age. Nephron Clin Pract. 2006.104(4):160-8.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Glassock, R.J., Winearls, C.G. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol. 2008. 3: 1563-1568.</mixed-citation><mixed-citation xml:lang="en">Glassock, R.J., Winearls, C.G. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol. 2008. 3: 1563-1568.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gunal AI, Kirciman E, Guler M, et al. Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? Ren Fail. 2004. 26(4): 405-9.</mixed-citation><mixed-citation xml:lang="en">Gunal AI, Kirciman E, Guler M, et al. Should the preservation of residual renal function cost volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? Ren Fail. 2004. 26(4): 405-9.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hanson JA, Hulbert-Shearon TE, Ojo AO, et al. Prescription of twice-weekly hemodialysis in the USA. Am J Nephrol. 1999. 19(6): 625-33.</mixed-citation><mixed-citation xml:lang="en">Hanson JA, Hulbert-Shearon TE, Ojo AO, et al. Prescription of twice-weekly hemodialysis in the USA. Am J Nephrol. 1999. 19(6): 625-33.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. American journal of kidney diseases. 1997. 30(3): 366-373.</mixed-citation><mixed-citation xml:lang="en">Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. American journal of kidney diseases. 1997. 30(3): 366-373.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Hoek FJ, Korevaar JC, Dekker FW, et al. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant. 2007 Jun. 22(6): 1633-8.</mixed-citation><mixed-citation xml:lang="en">Hoek FJ, Korevaar JC, Dekker FW, et al. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant. 2007 Jun. 22(6): 1633-8.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hur SM, Ju HY, Park MY, et al. Ferritin as a predictor of decline in residual renal function in peritoneal dialysis patients. Korean J Intern Med. 2014. Jul 29(4): 489-97.</mixed-citation><mixed-citation xml:lang="en">Hur SM, Ju HY, Park MY, et al. Ferritin as a predictor of decline in residual renal function in peritoneal dialysis patients. Korean J Intern Med. 2014. Jul 29(4): 489-97.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang HS, Hong YA, Yoon HE, et al. Comparison of Clinical Outcome Between Twice-Weekly and Thrice-Weekly Hemodialysis in Patients With Residual Kidney Function. Fourtounas. ed. Medicine. 2016. 95(7): e2767.</mixed-citation><mixed-citation xml:lang="en">Hwang HS, Hong YA, Yoon HE, et al. Comparison of Clinical Outcome Between Twice-Weekly and Thrice-Weekly Hemodialysis in Patients With Residual Kidney Function. Fourtounas. ed. Medicine. 2016. 95(7): e2767.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Iest CG, Vanholder RC, Ringoir SM. Loss of residual renal function in patients on regular haemodialysis. Int J Artif Organs. 1989. 12: 159-164.</mixed-citation><mixed-citation xml:lang="en">Iest CG, Vanholder RC, Ringoir SM. Loss of residual renal function in patients on regular haemodialysis. Int J Artif Organs. 1989. 12: 159-164.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005. Sep 20(9): 1880-8.</mixed-citation><mixed-citation xml:lang="en">Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant. 2005. Sep 20(9): 1880-8.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kalantar-Zadeh K, Unruh M, Zager PG, et al. Twice-Weekly and Incremental Hemodialysis Treatment for Initiation of Kidney Replacement Therapy. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2014. 64(2): 181-186.</mixed-citation><mixed-citation xml:lang="en">Kalantar-Zadeh K, Unruh M, Zager PG, et al. Twice-Weekly and Incremental Hemodialysis Treatment for Initiation of Kidney Replacement Therapy. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2014. 64(2): 181-186.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kang JS, Jang HR, Lee JE, et al. The bacterial colonization in tunneled cuffed dialysis catheter and its effects on residual renal function in incident hemodialysis patients. Clin Exp Nephrol. 2016. Apr. 20(2): 294-301.</mixed-citation><mixed-citation xml:lang="en">Kang JS, Jang HR, Lee JE, et al. The bacterial colonization in tunneled cuffed dialysis catheter and its effects on residual renal function in incident hemodialysis patients. Clin Exp Nephrol. 2016. Apr. 20(2): 294-301.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. In: Brenner B, ed. The Kidney. Philadelphia: W.B. Saunders Company. 2000: 1129-1170.</mixed-citation><mixed-citation xml:lang="en">Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. In: Brenner B, ed. The Kidney. Philadelphia: W.B. Saunders Company. 2000: 1129-1170.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">KDIGO, 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013. 3: 1-136.</mixed-citation><mixed-citation xml:lang="en">KDIGO, 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013. 3: 1-136.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney inter. 2013. 3: 259-305.</mixed-citation><mixed-citation xml:lang="en">Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney inter. 2013. 3: 259-305.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SY, Guijarro C, O'Donnell M, et al. Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int. 1995. 48: 363-371.</mixed-citation><mixed-citation xml:lang="en">Kim SY, Guijarro C, O'Donnell M, et al. Human mesangial cell production of monocyte chemoattractant protein-1: Modulation by lovastatin. Kidney Int. 1995. 48: 363-371.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Kjaergaard KD, Jensen JD, Peters CD, et al. Preserving residual renal function in dialysis patients: an update on evidence to assist clinical decision making. NDT Plus. 2011. 4(4): 225-230.</mixed-citation><mixed-citation xml:lang="en">Kjaergaard KD, Jensen JD, Peters CD, et al. Preserving residual renal function in dialysis patients: an update on evidence to assist clinical decision making. NDT Plus. 2011. 4(4): 225-230.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Levey, A.S., Bosch, J.P., Lewis, J.B. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999. 130: 461-470.</mixed-citation><mixed-citation xml:lang="en">Levey, A.S., Bosch, J.P., Lewis, J.B. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999. 130: 461-470.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Lin YF, Huang JW, Wu MS, et al. Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology (Carlton). 2009. 14(1): 59-64.</mixed-citation><mixed-citation xml:lang="en">Lin YF, Huang JW, Wu MS, et al. Comparison of residual renal function in patients undergoing twice-weekly versus three-times-weekly haemodialysis. Nephrology (Carlton). 2009. 14(1): 59-64.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Lindeman RD. Changes in renal function with aging. Implications for treatment. Drugs Aging. 1992. 2(5): 423-31. Review.</mixed-citation><mixed-citation xml:lang="en">Lindeman RD. Changes in renal function with aging. Implications for treatment. Drugs Aging. 1992. 2(5): 423-31. Review.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Liu, S., Diao, Z., Zhang, D. et al. Preservation of residual renal function by not removing water in new hemodialysis patients: a randomized, controlled study. Int Urol Nephrol. 2014. 46: 83.</mixed-citation><mixed-citation xml:lang="en">Liu, S., Diao, Z., Zhang, D. et al. Preservation of residual renal function by not removing water in new hemodialysis patients: a randomized, controlled study. Int Urol Nephrol. 2014. 46: 83.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Maschio G, Alberti Janin G, Locatelli F, et al. Effects of angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996. 334: 939-945.</mixed-citation><mixed-citation xml:lang="en">Maschio G, Alberti Janin G, Locatelli F, et al. Effects of angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996. 334: 939-945.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Milagros Fernández Lucas, José Luis Teruel, Gloria Ruíz-Roso, et al. Incremental Hemodialysis Schedule in Patients with Higher Residual Renal Function at the Start of Dialysis Advances in Nephrology. 2014. Article ID 236245: 6.</mixed-citation><mixed-citation xml:lang="en">Milagros Fernández Lucas, José Luis Teruel, Gloria Ruíz-Roso, et al. Incremental Hemodialysis Schedule in Patients with Higher Residual Renal Function at the Start of Dialysis Advances in Nephrology. 2014. Article ID 236245: 6.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Milutinovic J, Cutler R, Hoover P, et al. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis. Kidney Int 1975. 8: 185-190.</mixed-citation><mixed-citation xml:lang="en">Milutinovic J, Cutler R, Hoover P, et al. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis. Kidney Int 1975. 8: 185-190.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Morduchowicz, G., Winkler, J., Zabludowski, J.R. et al. Effects of residual renal function in haemodialysis patients. International Urology and Nephrology. 1994. 26: 125.</mixed-citation><mixed-citation xml:lang="en">Morduchowicz, G., Winkler, J., Zabludowski, J.R. et al. Effects of residual renal function in haemodialysis patients. International Urology and Nephrology. 1994. 26: 125.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002. 39: 191-266.</mixed-citation><mixed-citation xml:lang="en">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002. 39: 191-266.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015. 66(5): 884-930.</mixed-citation><mixed-citation xml:lang="en">National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015. 66(5): 884-930.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">National Kidney Foundation. KDOQI clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006. 48 Suppl. 1: S2-90.</mixed-citation><mixed-citation xml:lang="en">National Kidney Foundation. KDOQI clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006. 48 Suppl. 1: S2-90.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Nechita A-M, Rădulescu D, Peride I, et al. Determining factors of diuresis in chronic kidney disease patients initiating hemodialysis. Journal of Medicine and Life. 2015. 8(3): 371-377.</mixed-citation><mixed-citation xml:lang="en">Nechita A-M, Rădulescu D, Peride I, et al. Determining factors of diuresis in chronic kidney disease patients initiating hemodialysis. Journal of Medicine and Life. 2015. 8(3): 371-377.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Obi Y, Streja E, Rhee CM, et al. Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study. Am J Kidney Dis. 2016 Aug. 68(2): 256-65.</mixed-citation><mixed-citation xml:lang="en">Obi Y, Streja E, Rhee CM, et al. Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study. Am J Kidney Dis. 2016 Aug. 68(2): 256-65.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis. Annals of internal medicine. 2012. 157(4): 263-275.</mixed-citation><mixed-citation xml:lang="en">Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis. Annals of internal medicine. 2012. 157(4): 263-275.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Perl J, Bargman JM. The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis. 2009. 53: 1068-1081.</mixed-citation><mixed-citation xml:lang="en">Perl J, Bargman JM. The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis. 2009. 53: 1068-1081.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Pre-dialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999. 33: 507-517.</mixed-citation><mixed-citation xml:lang="en">Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Pre-dialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999. 33: 507-517.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Qiongqiong Yang, Ruixi Li, Zhewen Zhong, et al. Is cystatin C a better marker than creatinine for evaluating residual renal function in patients on continuous ambulatory peritoneal dialysis? Nephrol Dial Transplant. 2011. 26 (10): 3358-3365.</mixed-citation><mixed-citation xml:lang="en">Qiongqiong Yang, Ruixi Li, Zhewen Zhong, et al. Is cystatin C a better marker than creatinine for evaluating residual renal function in patients on continuous ambulatory peritoneal dialysis? Nephrol Dial Transplant. 2011. 26 (10): 3358-3365.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Rodrigues SD, França KC, Dallin FT, et al. N-acetylcysteine as a potential strategy to attenuate the oxidative stress induced by uremic serum in the vascular system. Life Sci. 2015. 15. 121: 110-6.</mixed-citation><mixed-citation xml:lang="en">Rodrigues SD, França KC, Dallin FT, et al. N-acetylcysteine as a potential strategy to attenuate the oxidative stress induced by uremic serum in the vascular system. Life Sci. 2015. 15. 121: 110-6.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Saeed A, Björkander E, Carlström J, et al. Hemodialysis twice versus three times a week in patients with residual kidney function: quality of life, cardiovascular outcomes and mortality. Göteborg: Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset, HTAcentrum. 2014. Regional activity-based HTA. 2014: 76.</mixed-citation><mixed-citation xml:lang="en">Saeed A, Björkander E, Carlström J, et al. Hemodialysis twice versus three times a week in patients with residual kidney function: quality of life, cardiovascular outcomes and mortality. Göteborg: Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset, HTAcentrum. 2014. Regional activity-based HTA. 2014: 76.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrology, dialysis, transplantation. 2002. 17 10. 1814-1818.</mixed-citation><mixed-citation xml:lang="en">Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrology, dialysis, transplantation. 2002. 17 10. 1814-1818.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Shafi T, Jaar BG, Plantinga LC, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis. 2010. 56: 348-358.</mixed-citation><mixed-citation xml:lang="en">Shafi T, Jaar BG, Plantinga LC, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study. Am J Kidney Dis. 2010. 56: 348-358.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004. 15: 1061-1070.</mixed-citation><mixed-citation xml:lang="en">Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol. 2004. 15: 1061-1070.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">United States Renal Data System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2016.</mixed-citation><mixed-citation xml:lang="en">United States Renal Data System. 2016 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2016.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Van Stone JC. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J. 1995. 41: M713-M716.</mixed-citation><mixed-citation xml:lang="en">Van Stone JC. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J. 1995. 41: M713-M716.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Vilar E, Wellsted D, Chandna SM, et al. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant. 2009. 24: 2502-2510.</mixed-citation><mixed-citation xml:lang="en">Vilar E, Wellsted D, Chandna SM, et al. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant. 2009. 24: 2502-2510.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Wong J, Sridharan S., Berdeprado J., et al. Predicting residual kidney function in hemodialysis patients using serum b-trace protein and b2-microglobulin. Kidney International. 2016. 89: 1090-1098.</mixed-citation><mixed-citation xml:lang="en">Wong J, Sridharan S., Berdeprado J., et al. Predicting residual kidney function in hemodialysis patients using serum b-trace protein and b2-microglobulin. Kidney International. 2016. 89: 1090-1098.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Wu CK, Yang YH, Juang JM, et al. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis. Medicine (Baltimore). 2015. Jan 94(3): e424.</mixed-citation><mixed-citation xml:lang="en">Wu CK, Yang YH, Juang JM, et al. Effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in dialysis patients: a nationwide data survey and propensity analysis. Medicine (Baltimore). 2015. Jan 94(3): e424.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis. 2008. 51: 373-384.</mixed-citation><mixed-citation xml:lang="en">Zhang L, Zhang P, Wang F, et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis. 2008. 51: 373-384.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
